Supernus Pharmaceuticals Inc (SUPN)
Debt-to-capital ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | 379,252 | 361,751 |
| Total stockholders’ equity | US$ in thousands | 1,035,730 | 921,516 | 886,204 | 815,851 | 744,858 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.32 | 0.33 |
December 31, 2024 calculation
Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $1,035,730K)
= 0.00
The debt-to-capital ratio of Supernus Pharmaceuticals Inc has shown a decreasing trend over the years based on the available data.
As of December 31, 2020, the ratio stood at 0.33, indicating that 33% of the company's capital structure was funded by debt. Subsequently, the ratio decreased to 0.32 by the end of December 31, 2021, showing a slight improvement in the company's debt utilization.
Starting from December 31, 2022, the debt-to-capital ratio dropped significantly to 0.00 and remained at this level for the following years up to December 31, 2024. This suggests that the company either reduced its debt levels substantially or increased its equity capital, leading to a debt-free capital structure during this period.
Overall, the declining trend in the debt-to-capital ratio indicates that Supernus Pharmaceuticals Inc has been progressively reducing its reliance on debt financing, which could potentially enhance its financial stability and solvency position in the long run.
Peer comparison
Dec 31, 2024